EUS-guided Celiac Plexus Neurolysis for the Treatment of Abdominal Pain in Pancreatic Cancer
EUS-guided Celiac Plexus Neurolysis for the Treatment of Abdominal Pain in Pancreatic Cancer
Studies have shown that injecting local anesthetics in areas rich in blood vessels increases
 the risk of drug injection into blood vessels by mistake and increases the systemic
 absorption of drugs, which may increase the incidence of central nervous system and
 cardiovascular system toxic events caused by local anesthetics.EUS-CPN-related complications
 have not been clearly associated with local anesthetic adverse events.However, EUS-CPN local
 anesthetic injection area is located around the beginning of the abdominal trunk with
 abundant large and small blood vessels. The choice of local anesthetics with higher safety
 than bupivacaine, such as ropivacaine, is of great significance to ensure the safety of
 eus-cpn, especially for eus-cpn beginners.At present, there are no reports on the application
 of ropivacaine in eus-cpn.
Inclusion Criteria:

 1. Aged between 18-75;

 2. Athologically confirmed as pancreatic cancer and clinically evaluated as advanced and
 unresectable;

 3. The visual analogue scale (VAS) for pain ≥ 4；

 4. Never received treatment for peritoneal plexus lesion or block；

 5. Voluntary signing of written informed consent

 Exclusion Criteria:

 1. Women during pregnancy；

 2. Cannot or refuses to sign the informed consent；

 3. Blood clotting disorder（PLT <50 × 103/μL, INR > 1.5）；

 4. Celiac infection；

 5. Severe esophageal or gastric varices and ulcers which may affect operation;

 6. The anatomical variation of the abdominal trunk abdominal aorta and could not be
 accurately located;

 7. Alcohol allergy

 8. Severe cardiopulmonary dysfunction and inability to tolerate the risk of intravenous
 anesthesia;

 9. History of mental illness;

 10. Patients with other chronic and acute diseases with unstable conditions that are
 expected to affect the efficacy evaluation and completion of the study.